Skip to main content
Fig. 1 | Thrombosis Journal

Fig. 1

From: The effect of recombinant versus plasma-derived von Willebrand factor on prolonged PFA closure times in ECMO patients with acquired von Willebrand syndrome – an observational study

Fig. 1

Effects of treatment with recombinant or plasma-derived VWF (rVWF vs. pVWF) on PFA COL/ADP closure time of samples from thirteen patients with ECMO-induced aVWS. The closure time was analyzed in-vitro on buffered citrate whole blood from ECMO patients spiked with rVWF or pVWF using the PFA-200 analyzer. If the time until hemostasis was longer than exactly quantifiable by the instrument, the highest value presented by the instrument was chosen for analysis. Data are presented as mean ± SEM. Data were analyzed by unpaired ANOVA. ns – not significant, ***p<0.001

Back to article page